StockMarketWire.com - Omega Diagnostics Group said it had generated positive results from an analysis of the design of a testing product for advanced HIV infections.

The company said it had therefore progressed into a formal optimisation phase within its design control programme.

'I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications,' chief executive Colin King said.

'I look forward to making further announcements as we bring this product to market.'


At 8:22am: [LON:ODX] Omega Diagnostics Group PLC share price was +0.5p at 13p



Story provided by StockMarketWire.com